Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Total Non-current Liabilities
All obligations due after more than one year.
Solventum CorporationNYSE: SOLV
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities falls 34.4% from a year ago
Total non-current liabilities stood at $5.78B at the end of Q2 FY2026, down 34.4% from a year earlier and down 0.0% from the prior quarter. Over 3 fiscal years it compounded at +124.3% a year.
Context
- Total non-current liabilities amounted to 40.6% of total assets at the end of Q2 FY2026, down 17.9 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -34.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 6.11B USD
- Year-over-year change
- -30.5%
- 4-year CAGR
- +77.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.11B | -30.5% |
| FY2024 | 2024-12-31 | 8.8B | +1502.0% |
| FY2023 | 2023-12-31 | 549M | +1.5% |
| FY2022 | 2022-12-31 | 541M | -11.3% |
| FY2021 | 2021-12-31 | 610M | — |
Total Non-current Liabilities vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's Jun 2026 total non-current liabilities of $5.78B is the 3rd highest of the 10 companies compared; the peer median is $2.48B.
- Its year-over-year change of -34.4% is the 9th highest of 10, against a peer median of -7.3%.
- Total non-current liabilities amounts to 40.6% of total assets for SOLV, versus a peer median of 30.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $15.62B | -27.8% | -8.4% | 30.8% | |
| Jun 2026 | $10.02B | -7.3% | -14.6% | 50.6% | |
| Jun 2026 | $5.78B | -34.4% | +124.3% | 40.6% | |
| Jun 2026 | $3.17B | +5.7% | +23.1% | 27.9% | |
| Mar 2026 | $2.7B | +20.3% | +1.1% | 51.7% | |
| Jul 2026 | $2.48B | -17.8% | +0.1% | 19.6% | |
| Oct 2026 | $1.71B | -1.5% | +14.6% | 30.4% | |
| Jun 2026 | $1.32B | -12.4% | -9.6% | 33.3% | |
| Sep 2026 | $915.27M | +5.1% | +42.3% | — | |
| Mar 2026 | $504K | -56.1% | -43.1% | 0.4% | |
| Peer median (excluding SOLV) | $2.48B | -7.3% | +0.1% | 30.6% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 91M | 61M | 194M | 762M | 878M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.18B | 1.17B | 1.31B | 1.23B | 1.03B |
| Inventory | 813M | 873M | 857M | 965M | 1.07B |
| Other Current Assets | 108M | 126M | 155M | 293M | 881M |
| Total Current Assets | 2.19B | 2.23B | 2.52B | 3.25B | 3.86B |
| Property, Plant & Equipment (Net) | 1.31B | 1.32B | 1.46B | 1.62B | 1.33B |
| Goodwill | 6.67B | 6.43B | 6.54B | 6.38B | 5.7B |
| Intangible Assets | 3.66B | 3.25B | 2.9B | 2.54B | 2.59B |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 253M | 358M | 530M | 665M | 813M |
| Total Non-current Assets | 11.89B | 11.36B | 11.42B | 11.21B | 10.44B |
| Total Assets | 14.08B | 13.59B | 13.94B | 14.46B | 14.29B |
| Account Payables | 320M | 348M | 477M | 618M | 687M |
| Short-term Debt | 0 | 27M | 0 | 200M | 0 |
| Tax Payables | 0 | 0 | 106M | 122M | 0 |
| Deferred Revenue | 0 | 559M | 574M | 572M | 621M |
| Other Current Liabilities | 732M | 312M | 365M | 659M | 1.83B |
| Total Current Liabilities | 1.41B | 1.31B | 1.73B | 2.7B | 3.14B |
| Long-term Debt | 0 | 0 | 8.3B | 7.81B | 5.04B |
| Deferred Tax Liabilities | 0 | 215M | 231M | 225M | 164M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 527M | 258M | (7.99B) | 760M | 910M |
| Total Non-current Liabilities | 610M | 541M | 549M | 8.8B | 6.11B |
| Total Liabilities | 2.02B | 1.85B | 2.28B | 11.5B | 9.25B |
| Common Stock | 0 | 0 | 0 | 2M | 2M |
| Retained Earnings | 0 | 0 | 0 | 242M | 1.8B |
| Accumulated OCI | (200M) | (497M) | (337M) | (1.06B) | (625M) |
| Other Stockholders Equity | 12.26B | 12.24B | 12B | 0 | 3.88B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 12.06B | 11.74B | 11.67B | 2.96B | 5.05B |
| Total Debt | 112M | 95M | 8.3B | 8.01B | 5.04B |
| Net Debt | 21M | 34M | 8.11B | 7.25B | 4.16B |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.